UroGen Pharma (NASDAQ:URGN) Rating Lowered to Neutral at HC Wainwright

UroGen Pharma (NASDAQ:URGN) was downgraded by equities research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, Marketbeat reports.

A number of other equities research analysts also recently issued reports on the company. The Goldman Sachs Group lowered their price target on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Guggenheim reiterated a “buy” rating on shares of UroGen Pharma in a report on Tuesday, April 29th. Scotiabank assumed coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price target on the stock. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, UroGen Pharma presently has an average rating of “Moderate Buy” and an average price target of $31.00.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $4.08 on Thursday. UroGen Pharma has a 1 year low of $3.42 and a 1 year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a 50 day moving average price of $10.18 and a 200 day moving average price of $10.73. The company has a market cap of $188.12 million, a price-to-earnings ratio of -1.30 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. Sell-side analysts predict that UroGen Pharma will post -3.12 earnings per share for the current year.

Institutional Trading of UroGen Pharma

Several large investors have recently bought and sold shares of URGN. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of UroGen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after purchasing an additional 2,983,368 shares in the last quarter. RTW Investments LP increased its stake in UroGen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock worth $40,841,000 after buying an additional 47,447 shares during the period. RA Capital Management L.P. acquired a new position in UroGen Pharma in the 1st quarter worth $35,461,000. Vestal Point Capital LP boosted its position in UroGen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock valued at $23,812,000 after buying an additional 522,957 shares during the last quarter. Finally, Toronto Dominion Bank acquired a new stake in shares of UroGen Pharma during the fourth quarter valued at about $18,628,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.